EMA Recommends Extension of Therapeutic Indications for Cetuximab By Ogkologos - August 14, 2026 129 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab February 26, 2021 Increased Risk of Cancer in Early Life Among Individuals with Autism... April 28, 2022 Bowel scope screening to stop in England January 14, 2021 New Cancer Model Shows Promise in Predicting If Treatment Will Shrink... July 28, 2022 Load more HOT NEWS Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma... Reflecting On My Time As the Cancer.Net Editor in Chief Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait
